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Abstract
Background: The aim of this study is to examine the influence of the catechol-O-methyltranferase
(COMT) gene (polymorphism Val158 Met) as a risk factor for Alzheimer's disease (AD) and mild
cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene
(APOE).
A total of 223 MCI patients, 345 AD and 253 healthy controls were analyzed. Clinical criteria and
neuropsychological tests were used to establish diagnostic groups.
The DNA Bank of the University of the Basque Country (UPV-EHU) (Spain) determined COMT
Val158 Met and APOE genotypes using real time polymerase chain reaction (rtPCR) and polymerase
chain reaction (PCR), and restriction fragment length polymorphism (RFLPs), respectively.
Multinomial logistic regression models were used to determine the risk of AD and MCI.
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BMC Neuroscience 2009, 10:125 http://www.biomedcentral.com/1471-2202/10/125Results: Neither COMT alleles nor genotypes were independent risk factors for AD or MCI. The
high activity genotypes (GG and AG) showed a synergistic effect with APOE ε4 allele, increasing the
risk of AD (OR = 5.96, 95%CI 2.74-12.94, p < 0.001 and OR = 6.71, 95%CI 3.36-13.41, p < 0.001
respectivily). In AD patients this effect was greater in women.
In MCI patients such as synergistic effect was only found between AG and APOE ε4 allele (OR =
3.21 95%CI 1.56-6.63, p = 0.02) and was greater in men (OR = 5.88 95%CI 1.69-20.42, p < 0.01).
Conclusion: COMT (Val158 Met) polymorphism is not an independent risk factor for AD or MCI,
but shows a synergistic effect with APOE ε4 allele that proves greater in women with AD.
Background
Genetic, metabolic and environmental factors play a role
in Alzheimer's disease (AD). The APOE ε4 allele is the
strongest genetic risk factor for sporadic forms of AD [1].
However, the APOE gene explains only a fraction of the
genetic risk associated with AD, and it is possible that
other genes or metabolic factors may modify the APOE ε4
effect to initiate the pathogenesis of AD. One of these can-
didate genes is the COMT (Catechol-O methyltransferase)
gene [2].
COMT is located on chromosome 22. It has 6 exons,
spans 27 kb and encodes a protein of 271 amino acids.
There is a single functional nucleotide polymorphism
(SNP) on exon 4 of the COMT gene: rs4680. This SNP is
characterised by low allele A activity (ATG/methionine)
and a (high activity) allele G (GTG/valine) in codon 158.
O-methylation mediation by COMT is an important
mechanism for inactivating estrogen. In contrast to the G
(high activity) allele, the A (low activity) allele causes the
accumulation of catecholestrogens [3].
In the last few years it has been suggested that estrogens
could be implicated in the etiology of AD through a
APOE-dependent mechanism. Estrogen effects upon the
central nervous system (CNS) are modulated via the estro-
gen receptors and metabolites. In mice, estradiol pro-
motes synaptic sprouting in response to an entorhinal
cortex lesion model of AD via an APOE-dependent mech-
anism [4]. Other evidences from animal studies also indi-
cates that 17-β-estradiol exerts a strong protective effect by
reducing neuronal apoptosis and inflammatory reponses
[5]. 17-β-estradiol activates protein kinase C (PKC) in rat
neuron cultures, and this activation is an important step
in estrogen protection against β-amyloid [6].
The important decrease in endogenous estrogens levels
after menopause may contribute to the development of
AD [7]. Data from population-based studies support the
hypothesis that estrogen replacement therapy is associ-
ated with a reduced prevalence of AD in postmenopausal
women [8,9]. These data suggest a protective effect of
estrogens upon AD.
Therefore, it is probable that genes such as COMT,
involved in estrogen metabolism are associated with a
greater likelihood of developing AD, and constitute
genetic risk markers.
Several studies have examined the relationships between
COMT polymorphisms and the risk of sporadic AD. Wang
et al. (2005) [10] found that COMT GG genotype and
APOE ε4 allele to exert a synergistic effect upon the risk of
AD. In addition, Borroni et al. [11] and Sweet et al. [12]
have determined that COMT genetic variation was associ-
ated with a risk of psychosis in AD.
The aim of the present study was to determine whether
COMT is linked to the risk of AD; whether there is an
interaction with APOE; and whether such interaction
could influence the risk of AD. Our hypothesis is that the
effect of COMT activity on estrogen levels may exist only
between high activity alleles of COMT (G alleles) and ε4
status carriers. Accordingly, we have studied this effect in
AD patients and in MCI patients, the latter condition pos-
sibly representing a prodrome for dementia [13].
With the purpose of examining the influence of COMT, a
gene involved in estrogen metabolism, as a genetic risk
factor for cognitive impairment, we conducted a study of
a sample of patients with mild cognitive impairment
(MCI), Alzheimer's disease (AD) and a control group. All
subjets were analyzed for COMT valine/methionine
(rs4680) polymorphism and APOE genotype.
Methods
This cross-sectional study comprised three subjects
groups: MCI patients (n = 223), AD patients (n = 345) and
healthy controls (n = 253). Subjets were prospectively
recruited from the Neurology Departments of several hos-
pitals. Participants were aged 50 years and older.
The subjects were evaluated using a broad battery of neu-
ropsychological tests: Minimental State Examination
(MMSE), Clinical Dementia Rating scale (CDR), CERAD
protocol, Stroop test, unilateral and bilateral motor
praxis, 7-minute test, trial making part A and B; and Neu-Page 2 of 9
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tia and AD (DSM IV and NINCDS-ADRDA) [14,15] and
Petersen's criteria for MCI, were used [13,16]. For AD and
MCI patients, evaluation also included routine blood
tests: haematology, biochemistry, thyroid-stimulating
hormone, vitamin B12 levels, syphilis serology and neu-
roimaging test (CT scan or MRI).
Based upon the results of these evaluations, the partici-
pants were classified into the following groups: MCI
patients, AD patients, and healthy control subjects.
A specific database was designed using Microsoft Access
2002 and declared to the Spanish Data Protection Agency.
The study was approved by the Ethics Committee of
Cruces Hospital. All patients signed informed consent to
undergo the examination. The study was conducted in
accordance with the Declaration of Helsinki concerning
medical research in human subjects.
MCI patients
The diagnosis was based on Petersen's criteria. Patients
had memory complaints corroborated by an informant,
representing a decline from a previous level of functioning
given their age and educational level. The score in CDR
scale was required to be 0.5, and performance in relation
to other cognitive functions and daily living activities were
required to be normal.
AD patients
The diagnosis of AD was based on the DSM IV [14] and
NINCDS-ADRDA [15] criteria for probable and possible
AD. Patients with a total score of less than 3 on CDR scale
(mild to moderate dementia) were included.
Healthy control subjects
These subjects scored within the normal ranges for age
and educational level in psychometric testing, with a CDR
score of 0.
The exclusion criteria included: previous cerebrovascular
diseases (transient ischemic attacks, stroke or intracranial
haemorrhage), other neurodegenerative diseases, severe
comorbidities making adequate follow-up unlikely, acute
psychiatric diseases, and the absence of a reliable inform-
ant.
Genetic analysis
On the first visit, peripherical blood samples were col-
lected at EDTA vacuum tubes from all individuals.
Genomic DNA was extracted from white blood cells using
standard phenol/chloroform extraction method. Then
COMT Val158 Met (rs4680) and APOE genotypes were
analyzed blinded to clinical diagnosis.
APOE was amplified by PCR with the primers 112F and
158R, under the PCR conditions described by Wilton and
Lim [17]. Digestion of the amplified product was carried
out with Hae II and Afl III, as described by Álvarez-Álvarez
et al. [18]. COMT genotyping was done using 5'-nuclease
allelic discrimination assay on the ABI Prism 7000
Sequence Detection System. Taqman SNP genotyping
products and Custom Taqman SNP Genotyping Assays
were used. Reactions were done with the following proto-
col: 95°C for 10 min, 45 cycles at 95°C for 15 sec, and
58°C for 1 min 30 sec.
Statistical analysis
Genepop software version 4.0 was used to calculate geno-
typic and allelic frequencies and to test the goodness of fit
of patients and control samples to Hardy-Weinberg equi-
librium by means of the exact test of Guo and Thompson
[19].
Statistical analysis was also performed using the SPSS®
package, version 15.0. Differences among demographic
and clinical variables were evaluated using the chi-
squared test and analysis of variance (ANOVA). A dichot-
omous variable was used for each polymorphism: "yes" or
"no" for "carrier" or "no carrier" of the APOE ε4 allele and
for different alleles and genotypes from the COMT gene.
A multinonial regression model was created in order to
determine the independent effect of any COMT allele and
genotypes in the absence of ε4 allele; and the effect of ε4
allele in the total sample and a sample selected by at least
one ε4 allele and no G COMT allele. Another model was
created to evaluate the combined effect of ε4 allele and
COMT genotypes, based on the hypothesis that the effect
of estrogens might exists only in ε4 carriers. In all these
models the reference categories were controls, females
and the absence of ε4 and G COMT allele. P-values of less
than 0.05 were considered statistically significant.
Results
We have investigated the independent and combined
association of COMT Met108/158Val and APOE using a
case-control design.
In the present study we analyzed a sample of 223 MCI
patients, 345 AD patients, and 253 healthy control sub-
jects without significant differences in terms of age (p >
0.05).
The MMSE scores for MCI, AD patients and controls were
26.58 ± 2.16, 19.72 ± 4.80 and 28.23 ± 1.73 respectively
(p < 0.05) (Table 1).
Table 2 shows the allele and genotype frequencies of
COMT and APOE genes in MCI, AD and controls. In allPage 3 of 9
(page number not for citation purposes)
BMC Neuroscience 2009, 10:125 http://www.biomedcentral.com/1471-2202/10/125studied groups, the COMT genotype frequencies were in
Hardy-Weinberg equilibrium (p > 0.05). There were no
significant differences in allele and genotype frequencies
in MCI and AD compared to controls for COMT gene,
while the differences proved significant for APOE gene
(Table 3).
In order to determine whether COMT G allele is an inde-
pendent risk factor for MCI and AD, we selected a sub-
group of MCI, AD and control individuals with the
presence of at least one COMT G (high activity) allele and
the absence of APOE ε4 allele.
The odds ratios (ORs) of developing MCI and AD were
0.90 (95%CI 0.53-1.51, p < 0.68) and 1.24 (95%CI 0.74-
2.08, p = 0.42), respectively (Table 4). In subsequent anal-
yses we obtained that any COMT genotype with at least
one high activity allele (G) had a significative effect (data
not shown).
APOE ε4 allele is a risk factor for cognitive impairment,
and this risk is lower in MCI (OR = 2.53, 95%CI 1.69-3.79
p < 0.001) than in AD (OR = 4.37, 95%CI 3.02-6.33 p <
0.001). The higher risk conferred by allele APOE ε4 was
Table 1: Baseline demographics.
Group Agea Women (%)b MMSEc
MCI 74.10 ± 8.81 60.3 26.58 ± 2.16
AD 74.95 ± 7.83 71.4 19.72 ± 4.80
CONTROLS 74.94 ± 10.34 59.6 28.23 ± 1.73
a Years, mean ± standard deviation (SD). b % of women in group. c 
MMSE score, mean ± standard deviation.
Table 2: Allele and genotype frequency.
COMT MCIa (n = 223) ADb (n = 345) Controls (n = 253)
Allele A 0.520 0.470 0.512
G 0.480 0.530 0.488
Genotype AA 0.278 0.214 0.265
AG 0.484 0.510 0.494
GG 0.238 0.275 0.241
H-Wa p-Value 0.69 0.75 0.90
APOE MCIa (n = 223) ADb (n = 345) Controls (n = 253)
Allele 2 0.027 0.035 0.059
3 0.731 0.664 0.838
4 0.242 0.301 0.103
Genotype 2.2 0.000 0.000 0.008
2.3 0.045 0.052 0.095
2.4 0.009 0.017 0.008
3.3 0.561 0.432 0.692
3.4 0.296 0.412 0.198
4.4 0.090 0.087 0.000
H-Wc p-value 0.07 0.85 0.11
aMCI: mild cognitive impairment. bAD: Alzheimer's disease. cHardy-Weinberg probability test.Page 4 of 9
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MCI women (OR = 2.46, 95%CI 1.45-4.15 p < 0.001) ver-
sus AD women (OR = 5.10, 95%CI 3.20-8.13 p < 0.01)
and MCI men (OR = 2.59, 95%CI 1.36-4.92 p < 0.04) ver-
sus AD men (OR = 3.19, 95%CI 1.72-5.91 p < 0.001).
Aiming to avoid the combined effect of COMT genotypes
and allele APOE ε4, we analyzed the risk of MCI and AD
according to the presence of at least one APOE allele ε4
and the absence of COMT G allele. The OR for MCI and
AD were OR = 1.64, 95%CI 0.80-3.36, p = 0.18, and OR =
2.61, 95%CI 1.31-5.18, p < 0.01 respectively. These results
could indicate a synergistic interaction between APOE ε4
and COMT G in MCI and AD patients.
We further evaluated a possible synergistic effect between
COMT and APOE by using a multivariate logistic regres-
sion model. To this effect, we subgrouped the subjets
according to the high activity genotypes of COMT (GG or
AG) and the presence of at least one APOE ε4 allele.
A synergistic effect between genotypes GG and AG with
APOE ε4 was observed in AD patients (OR = 5.96, 95%CI
2.74-12.94, p < 0.001 and OR = 6.71 95%CI 3.36-13.41,
p < 0.001 respectively). This effect is most notorious is
women for both genotypes GG and AG (OR = 11.50,
95%CI 3.83-34.53, p < 0.001 and OR = 7.94 (95%CI
3.24-19.42, p < 0.01 respectively).
In MCI patients, this synergistic effect was only found
between AG and APOE ε4 (OR = 3.21 95%CI 1.56-6.63, p
= 0.02) and was greater in men (OR = 5.88 95%CI 1.69-
20.42, p < 0,01) (Table 4).
Discussion
Our study shows that neither COMT alleles nor genotypes
are independently associated with the risk of AD or MCI,
but confirms an association between high activity alleles
of COMT (G alleles), ε4 status carriers and the risk of AD.
This effect is moreover greater in AD women.
In our series, APOE ε4 allele is seen to be an independent
risk factor for the AD population, and this risk is highest
for women. The APOE ε4 allele also constitutes a risk fac-
tor for MCI patients. On evaluating the independent effect
of the APOE ε4 allele in the absence of COMT genotype G,
the risk for AD remains; though the association with the
risk of MCI is lost.
We have found the GG and AG genotypes to exert a syner-
getic effect with APOE ε4. When these genotypes are
included into the multinomial analysis, the risk of AD in
APOE ε4 allele and GG or AG carriers increases, and is
more pronounced in women. The risk for MCI is only
found in APOE ε4 allele and AG carriers, and is more
notorious in men.
To our knowledge, only two previous studies have evalu-
ated the role of COMT polymorphism as a risk factor for
AD [10,20]. The first study was conducted in Colombia by
Forero et al. [20], and an initial association between AA
low activity genotype and the risk of AD males (OR = 2.76,
Table 3: Exact G test, allele and genotype frequencies.
COMTa COMTb
p-value S.E.c p-value SEc
MCI vs controls 0.85 <0.001 MCI vs controls 0.85 <0.001
MCI vs AD 0.11 <0.001 MCI vs AD 0.10 <0.001
AD vs controls 0.16 <0.001 AD vs controls 0.16 <0.001
APOEa APOEb
p-value SEc p-value SEc
MCI vs controls 0.00 <0.001 MCI vs controls 0.00 <0.001
MCI vs AD 0.06 <0.001 MCI vs AD 0.06 <0.001
AD vs controls 0.00 <0.001 AD vs controls 0.00 <0.001
a Allele frequency. bGenotype frequency. c Standard error.Page 5 of 9
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associations were lost after Bonferroni correction for mul-
tiple testing.
Our findings are in accordance with the second study per-
formed by Wang et al. [10]. These authors established that
the GG genotype (COMT HH) and the presence of at least
one APOE ε4 allele exerted a synergetic effect, increasing
the risk of AD to 3.6 (95%CI 1.2 - 10.6). They postulated
that the existence of the COMT HH genotype is a impor-
tant modulating factor for the increased risk of developing
AD. The sample size of our study allows a stratification by
sex. In our series, similar ranges of values have been
obtained for the most high activity genotypes (AG and
GG), and mainly women with AD
There is considerable evidence suggesting that allele ε4
constitutes a major susceptibility factor for the develop-
ment of AD [1]. Some authors [21] have shown the APOE
ε4 allele to be associated with an increased risk of MCI
(OR: 6.04, 95%CI: 2.76-3.23; p < 0.001), though with no
effect upon the probability of evolving AD. Despite the
fact that the presence of the APOE ε4 allele has been asso-
ciated with an increased risk of conversion from MCI to
AD, the sensitivity is quite low [22]. The APOE ε4 allele is
an important risk factor for AD, and may be useful for pre-
dicting who is likely to progress to dementia [23]. How-
ever, APOE ε4 carriers do not always develop dementia,
and APOE ε4 carrier status in itself was not found to be
predictive of cognitive decline or conversion to AD from
MCI [24]. The role of APOE in brain repair mechanisms
might be associated with the risk for AD, the ε4 allele
being less effective in synaptic remodeling, repair, and
regeneration after brain injuries [25].
Several studies have shown an interaction between estro-
gen and APOE. Sex-specific incidence rates for AD are
higher in women after menopause than in men [26],
probably due to lack of estrogens, and the APOE ε4 allele
is associated with a greater decline in cognitive functions
Table 4: Risk factors for MCI and AD. Logistic regression models.
MCI AD
Independent effects OR IC95% P OR IC95% p
G (+) NO E4 (+)a 0.90 (0.53-1.51) 0.68 1.24 (0.74-2.08) 0.42
E4 (+)b 2.53 (1.69-3.79) <0.001 4.37 (3.02-6.33) <0.001
E4 (+)*Womenb1 2.46 (1.45-4.15) <0.001 5.10 (3.20-8.13) <0.001
E4 (+)*Menb2 2.59 (1.36-4.92) 0.04 3.19 (1.72-5.91) <0.001
E4 (+) NO COMT_Gb3 1.64 (0.80-3.36) 0.18 2.61 (1.31-5.18) <0.01
MCI AD
Synergistic effects OR IC95% p OR IC95% p
E4 (+) * GGc 2.11 (0.90-4.95) 0.08 5.96 (2.74-12.94) <0.001
E4 (+) * AGc 3.21 (1.56-6.63) 0.02 6.71 (3.36-13.41) <0.001
E4 (+) * GG * WOMENd 2.00 (0.60-6.67) 0.26 11.50 (3.83-34.53) <0.001
E4 (+) * GG * MENd 3.30 (0.88-12.35) 0.07 2.14 (0.64-7.20) 0.22
E4 (+) * AG * WOMENd 2.40 (0.96-6.00) 0.06 7.94 (3.24-19.42) <0.001
E4 (+) * AG * MENd 5.88 (1.69-20.42) <0.01 5.36 (1.76-16.28) <0.01
a Sample selected by at least one COMT genotype and absence of E4. Reference category was sample control. b Total sample with any exclusion, 
control sample was reference. b1 Total sample with any exclusion, female control sample was reference. b2 Total sample with any exclusion, male 
control sample was reference. b3Sample selected by at least one E4 and none COMT G allele. Reference category was sample control. c Sample 
selected by at least one E4 and COMT genotype. d Sample selected by at least one E4, COMT genotype and gender. *In all cases, reference category 
was control sample.Page 6 of 9
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ences in APOE-associated risk for AD [27]. Estrogen use
was associated with a lesser cognitive decline among ε4-
negative women [28].
The biological mechanisms underlying the effect of
COMT gene upon the risk of AD fall beyond the scope of
the present study, though different hypotheses could be
postulated based on the literature. Worda et al. 2003 [29]
showed that women with an high activity genotype (GG)
present lower serum estrogen concentration. Therefore,
this genotype could be correlated to a lesser neuroprotec-
tive effect, and differences in COMT genotype might be
involved in causing variable effects of estrogens upon dis-
eases. 17-β-estradiol is metabolized via two major path-
ways: 16-alpha-hydroxilation or the formation of
cathecholestrogens [30]. COMT enzyme participates in
the metabolism of estrogens after their hydroxylation to
catecholestrogens by forming O-methyl derivates [3].
Thus, polymorphism in the COMT gene affecting the
activity of the enzyme could alter the levels of cathecoles-
trogens and consequently the estrogen neuroprotective
effect.
The ways in which COMT overactivity may interact with
APOE ε4 comprise the lowering of brain estrogen levels.
Tau hyperphosphorylation is proposed to be an early
event characteristic of AD and other neurodegenerative
diseases [31]. The neurofibrillary tangles present in AD
consist mainly of hyperphosphorylated microtubule-
associated protein tau [32]. 17 β-estradiol exerts a neuro-
protective effect through the inactivation of GSK-3β,
which is the kinase most implicated in tau hiperphospho-
rylation [33].
Another possible mechanism of action of estrogen is
related to oxidative stress. Eichi et al. [34] demonstrated
that catecholestrogens were catechol metabolites of 17-β
estradiol that induced DNA adducts. Oxidative damage
may be an early event in the pathogenesis of AD when the
balance between free radical generation and antioxidant
capacities shifts toward free radical production [35]. This
fact is already evident in early AD [36]. Finally, excessive
COMT activity may induce saturation of methylation
capacity, deficient methylation capacity having been
linked to neurodegeneration. The metabolism of levo-
dopa down the COMT pathway has been speculated to
result in the saturation of cellular methylation capacity in
Parkinson's disease (PD) and in accelerated cognitive
decline and dementia [37].
The distinction between APOE ε4 carriers and non-carriers
in AD and MCI appears to be increasing in importance: in
MCI, the risk of cognitive decline and progression to AD
seems to be greatest in individuals who carry at least one
copy of both the BCHE-K and APOE ε4 alleles. In a recent
paper [37], APOE ε4 and butyrylcholinesterase-K (BuChE-
K) were associated with an increased risk for cognitive
decline in patients with Parkinson's Disease Dementia
(PDD) [38]
Pharmacogenomics and the study of interindividual
genetic variability, which plays a significant role in defin-
ing drug response and toxicity, could exert a potential
influence upon the design of more efficacious and safe
treatments. Rosiglitazone [39] and passive antibodies tar-
geted to beta-amyloid peptide [40] have elicited treatment
response in non-ε4 carriers with mild to moderate AD.
Some limitations to our study must be adressed. The main
limitation is that the study population comes from the
hospital setting. A community-based study could provide
more information. The serum leves of estradiol have not
been measured, and we do not know whether the patients
received estrogen replacement therapy in the last years.
We also include a sample of patients with MCI, which is
probably a heterogeneous clinical entity. Not all the sub-
jects in this group develop AD, and some of them return
to a normal cognitive status. More operational criteria for
this clinical entity are nedeed. Such a lack of operational
criteria could explain our discordant results in this partic-
ular population (more risk for men than women). Accord-
ingly, prospective studies might elucidate not only the
role of COMT genotypes in AD, but also in the evolution
of cognitive impairment from the early stages.
Our study also may be biased by the fact that the recruited
MCI subjects could be in different stages of the disease,
and individuals with a increased COMT activity genotype
and APOE ε4 carrier status can convert more rapidly to
AD, such individuals being under-represented in the MCI
sample. This may explain the lower risk associated with
the GG versus the AG genotype in MCI ε4 carriers.
The strengths of our study are its multicenter nature
including AD patients, healthy controls, and for the first
time MCI patients. Moreover, the patient sample is not
small, and the number of cases allows gender stratifica-
tion.
The activity of the main enzymes implicated in acetylcho-
line metabolims (acetylcholine esterase and choline
acetyltranferase) is affected by estrogen administration
[41,42]. Based on this interaction between APOE and
COMT genotypes, it could be possible to identify
responder patients, that could derive more benefit from
acetylcholinesterase inhibitors, actually the main treat-
ment for AD. If the interaction between APOE ε4 and
COMT genotypes in patients with AD is confirmed byPage 7 of 9
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by regulating synaptic dysfunction and estrogen metabo-
lism. Treatments that reduce COMT activity might prove
useful in the treatment of AD or in preventing the progres-
sion from MCI to AD, especially in women. Elucidation of
the mechanisms whereby increased COMT activity influ-
ences neurodegenerative processes in ε4 carriers might
help clarify etiological mechanisms in AD.
Conclusion
In conclusion, COMT (Val158 Met) polymorphism is not
an independent risk factor for AD or MCI, but exerts a syn-
ergistic effect with the APOE ε4 allele which is greater in
women with AD. In MCI patients, this synergistic effect
was only found between AG and APOE ε4, and was greater
in men.
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